Study Status: COMPLETED
Recruit Status: COMPLETED
Study Type: INTERVENTIONAL
Official Title: Prophylactic Tranexamic Acid (TXA) Administration in Patients Undergoing Caesarean Delivery (CD).
Brief Summary: This is a prospective, double-blinded, randomized placebo-controlled trial.
The study will be approved by the DUHS institutional review board (IRB) and the trial will be registered at clinical trial registry.
After receiving the trial information from the obstetricians during prenatal visits or from the anaesthetists during the systematic anaesthesia visit, or both the prospective women will be invited to participate in the trial.
The intervention consists of administration of 1gm of tranexemic acid (TXA) or 10-mls of placebo (normal saline) intravenously, according to the randomization groups slowly over 30-60 sec, within 3 mins of the delivery of baby, after the routine prophylactic uterotonic administration and cord clamping.
Administration of the prophylactic uterotonic agent (and TXA or placebo) may be followed by a two-hour oxytocin infusion, in accordance with the hospital policy.
All women will be followed up at 48 hours after caeserian delivery.
A venous blood sample will be obtained on day-two (D2) after delivery for outcome assessment.
Adverse events will be assessed until hospital discharge and by telephone interview at 8 weeks after delivery.